Certification ensures highest level of patient data security a medical device can attain
TELFORD, Pa., Aug. 11, 2025 /PRNewswire/ — Today Dräger, an international leader in medical and safety technologies, announced that the company’s Atlan A350/A350 XL series of anesthesia workstations received Authority to Operate (ATO) certification under the Department of Defense’s (DoD) Risk Management Framework (RMF) eMASS #4060.
“Cyberattacks continue to be a serious threat to hospitals – both clinically and financially,” said President and CEO for Draeger, Inc., Lothar Thielen. “To help hospitals meet this challenge, Dräger embeds the latest cybersecurity technology deeply into our development processes. Our new Atlan anesthesia workstations now carry ATO certification, which is the highest level of security a medical device can hold.”
Continuing a longstanding commitment to patient data security
Certification of Dräger’s Atlan A350/A350XL anesthesia workstation follows the certifications of the Perseus A500 (eMASS # 2852) and Fabius MRI (eMASS # 2875) anesthesia workstations. Now with the Atlan certification, Dräger anesthesia customers can have confidence knowing that Dräger’s entire anesthesia machine portfolio has gone through this rigorous cyber-security review process.
Benefits of ATO-certified medical devices
Medical devices that have achieved an Authority to Operate (ATO) under the Risk Management Framework (RMF) offer significant advantages to hospitals, including:
These benefits enable ATO-certified medical devices to provide stronger patient data protection and carry a lower risk of cyberattacks.
More information:
Dräger Atlan A350/A350 XL family of devices:
https://www.draeger.com/en-us_us/Products/Atlan-A350-US-Version
You can find more information and pictures in our press center:
https://www.draeger.com/en-us_us/Newsroom/Press-Center
Dräger. Technology for Life.
Dräger is a leading international medical and safety technology company. Our products protect, support and save lives. Founded in Lübeck, Germany in 1889, Dräger generated global sales of around EUR 3,4 billion in 2024. The Lübeck-based company is represented in more than 190 countries and employs more than 16,000 people worldwide. For more information, visit www.draeger.com
Contact
Communications: Melanie Kamann, Tel. +49 451 882-3202, melanie.kamann@draeger.com
Press Contact North America: Laura Edwards, Tel. +1 215 565-5868, laura.edwards@draeger.com
Investor Relations: Thomas Fischler, Tel. +49 451 882-2685, thomas.fischler@draeger.com
SOURCE Draeger
ATLANTA, GA AND DOHA, QATAR / ACCESS Newswire / December 6, 2025 / Ameerex Corporation…
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…